A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Summary

The study in the labeled and real conditions of prescription of Actonel will investigate the satisfaction of patients with its new formulation: 35 mg Once A Week. The study will also measure response rates in CTX (the C-telopeptide of type I collagen) at baseline and after 12 weeks of treatment with risedronate 35 mg Once A Week.

Timeline

Start

2004-05

Primary completion

—

Completion

2006-05

Drugs

Indications